Published in Front Neuroanat on September 14, 2010
Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun (2014) 1.10
Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci (2014) 0.91
Dopaminergic modulation of striatal networks in health and Parkinson's disease. Curr Opin Neurobiol (2014) 0.86
Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. J Pharmacol Exp Ther (2011) 0.81
Neurobehavioral assessment of mice following repeated postnatal exposure to chlorpyrifos-oxon. Neurotoxicol Teratol (2012) 0.78
Parkinson's disease: general features, effects of levodopa treatment and future directions. Front Neuroanat (2010) 0.78
Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease. Mov Disord (2016) 0.77
Basal Ganglia Circuits: What's Now and Next? Front Neuroanat (2012) 0.75
Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci (1986) 18.17
The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28
The role of the basal ganglia in habit formation. Nat Rev Neurosci (2006) 8.68
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (1990) 8.07
Primate models of movement disorders of basal ganglia origin. Trends Neurosci (1990) 7.63
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature (2010) 7.35
The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol (1996) 7.24
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med (2000) 6.21
Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci (2000) 6.02
Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res (1990) 5.79
Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol (2006) 5.40
Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev (1995) 5.23
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
Circuits and circuit disorders of the basal ganglia. Arch Neurol (2007) 3.97
Different time courses of learning-related activity in the prefrontal cortex and striatum. Nature (2005) 3.84
Central mechanisms of motor skill learning. Curr Opin Neurobiol (2002) 3.84
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol (1994) 3.42
Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res (2002) 3.34
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord (2001) 2.89
Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci (1989) 2.83
Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem (1991) 2.66
Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J Neurosci (2006) 2.64
Network modulation in the treatment of Parkinson's disease. Brain (2006) 2.52
Changes in network activity with the progression of Parkinson's disease. Brain (2007) 2.46
Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol (1996) 2.45
Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol (2002) 2.37
Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res (1979) 2.36
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 2.28
Histochemical changes in cytochrome oxidase of cortical barrels after vibrissal removal in neonatal and adult mice. Proc Natl Acad Sci U S A (1980) 2.16
Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci (2009) 2.16
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci (1998) 2.10
D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol (1995) 2.01
Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci (1990) 1.96
Regulation of gamma-aminobutyric acid synthesis in the brain. J Neurochem (1993) 1.86
Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage (2006) 1.84
L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Trans Am Neurol Assoc (1968) 1.76
Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci (2000) 1.73
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci (2001) 1.72
The cortico-striate projection in the monkey. Brain (1970) 1.72
Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci (2008) 1.71
Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci (2004) 1.67
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience (1989) 1.64
Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol (1999) 1.64
Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog Brain Res (2004) 1.58
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci (2001) 1.57
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci (2008) 1.56
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2002) 1.54
Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience (2005) 1.51
Metabolic correlates of levodopa response in Parkinson's disease. Neurology (2001) 1.50
Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J Neurosci (1998) 1.47
The structure of the caudate nucleus of the cat: light and electron microscopy. Philos Trans R Soc Lond B Biol Sci (1971) 1.45
FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage (2005) 1.40
Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol (1987) 1.39
Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci (2000) 1.31
Monosynaptic inputs to caudate neurons identified by intracellular injection of horseradish peroxidase. Brain Res (1976) 1.28
Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp (2003) 1.23
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol (2000) 1.18
Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism. Eur J Neurosci (2008) 1.14
Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol (2008) 1.14
Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res (1988) 1.14
Efferent connections of the centromedian and parafascicular thalamic nuclei in the squirrel monkey: a PHA-L study of subcortical projections. J Comp Neurol (1992) 1.13
The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc Natl Acad Sci U S A (2005) 1.13
Regulatory properties of brain glutamate decarboxylase (GAD): the apoenzyme of GAD is present principally as the smaller of two molecular forms of GAD in brain. J Neurosci (1991) 1.13
Efferent projections of the subthalamic nucleus in the squirrel monkey as studied by the PHA-L anterograde tracing method. J Comp Neurol (1990) 1.12
Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. J Comp Neurol (2000) 1.11
Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. J Neurophysiol (2000) 1.10
Afferent projections to the cholinergic pedunculopontine tegmental nucleus and adjacent midbrain extrapyramidal area in the albino rat. I. Retrograde tracing studies. J Comp Neurol (1992) 1.09
Evidence for a direct subthalamo-cortical loop circuit in the rat. Eur J Neurosci (2008) 1.08
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J Neurosci (2006) 1.07
Excitatory amino acids in synaptic excitation of rat striatal neurones in vitro. J Physiol (1988) 1.06
The organization of the descending ventral pallidal projections in the monkey. J Comp Neurol (1993) 1.05
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain (2001) 1.05
Cellular principles underlying normal and pathological activity in the subthalamic nucleus. Curr Opin Neurobiol (2006) 1.05
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids (2002) 1.05
Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience (1987) 1.04
Efferent connections of the internal globus pallidus in the squirrel monkey: I. Topography and synaptic organization of the pallidothalamic projection. J Comp Neurol (1997) 1.01
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci (2005) 1.01
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry (2006) 1.00
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol (2003) 0.99
A glutamatergic corticostriatal path? Brain Res (1977) 0.99
Efferent projections of the subthalamic nucleus: an autoradiographic study in monkey and cat. J Comp Neurol (1978) 0.98
Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: Ipsi- and contralateral projections. J Comp Neurol (2005) 0.97
Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and nucleus tegmenti pedunculopontinus in the rat. Neuroscience (1983) 0.96
Study of projections from the entopeduncular nucleus to the thalamus of the rat. J Comp Neurol (2000) 0.96
Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res (1991) 0.96
Basal ganglia pathophysiology. A critical review. Adv Neurol (1997) 0.95
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol (1999) 0.95
Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems. Neurosci Lett (1984) 0.93
Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration. Neurobiol Dis (2005) 0.92
Glutamatergic pallidothalamic projections and their implications in the pathophysiology of Parkinson's disease. Neurobiol Dis (2008) 0.91
Organization of efferent projections from the internal segment of globus pallidus in primate as revealed by fluorescence retrograde labeling method. Brain Res (1982) 0.91
Two forms of rat brain glutamic acid decarboxylase differ in their dependence on free pyridoxal phosphate. J Neurochem (1985) 0.91
Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience (1995) 0.90
Nigral and pallidal inputs to functionally segregated thalamostriatal neurons in the centromedian/parafascicular intralaminar nuclear complex in monkey. J Comp Neurol (2002) 0.90
Nigral innervation of cholinergic and glutamatergic cells in the rat mesopontine tegmentum: light and electron microscopic anterograde tracing and immunohistochemical studies. J Comp Neurol (1998) 0.89
A direct projection from the subthalamic nucleus to the ventral thalamus in monkeys. Neurobiol Dis (2010) 0.89
Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus. Eur J Neurosci (2004) 0.89
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol (2014) 2.33
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 2.28
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A (2012) 2.16
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol (2009) 1.70
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 1.65
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. Mov Disord (2012) 1.51
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J Neurosci (2012) 1.43
Coordinated reset has sustained aftereffects in Parkinsonian monkeys. Ann Neurol (2012) 1.42
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci (2007) 1.35
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci (2004) 1.30
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
Shaping of motor responses by incentive values through the basal ganglia. J Neurosci (2007) 1.24
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med (2010) 1.23
Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol (2008) 1.19
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol (2002) 1.17
The nigrostriatal pathway in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol (2009) 1.13
Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord (2005) 1.13
Microarray analysis of nonhuman primates: validation of experimental models in neurological disorders. FASEB J (2003) 1.13
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci (2009) 1.09
Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One (2010) 1.08
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry (2008) 1.07
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J Neurosci (2006) 1.07
Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate. PLoS One (2010) 1.07
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis (2007) 1.06
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A (2010) 1.05
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis (2010) 1.04
Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radic Biol Med (2005) 1.04
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci (2008) 1.02
Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry (2007) 1.01
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci (2005) 1.01
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci (2005) 1.00
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry (2009) 1.00
Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain (2011) 1.00
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry (2006) 1.00
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis (2006) 0.99
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest (2012) 0.98
Traditional Chinese medicine for Parkinson's disease: a review of Chinese literature. Behav Pharmacol (2006) 0.97
Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol Neurobiol (2003) 0.96
Protein aggregation in the aging retina. J Neuropathol Exp Neurol (2011) 0.96
Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat Disord (2009) 0.96
Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol (2004) 0.94
Modeling Parkinson's disease in primates: The MPTP model. Cold Spring Harb Perspect Med (2012) 0.94
Misrepresentation of neuroscience data might give rise to misleading conclusions in the media: the case of attention deficit hyperactivity disorder. PLoS One (2011) 0.92
Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol (2011) 0.91
Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. J Neurosci (2007) 0.90
Altered pallido-pallidal synaptic transmission leads to aberrant firing of globus pallidus neurons in a rat model of Parkinson's disease. J Physiol (2012) 0.90
Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. Eur J Neurosci (2006) 0.90
Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci (2004) 0.89
New animal models of Parkinson's disease. Mov Disord (2011) 0.89
Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. Eur J Pharmacol (2003) 0.89
Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem (2008) 0.89
IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTP. Neurobiol Aging (2008) 0.88
Behavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders? PLoS One (2013) 0.88
Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy (2012) 0.88
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS One (2008) 0.87
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther (2004) 0.87
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS One (2010) 0.87
Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria. J Biol Chem (2005) 0.86
A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov Disord (2012) 0.86
Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol (2006) 0.85
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse (2010) 0.85
Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann Neurol (2013) 0.84
Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. BMC Bioinformatics (2006) 0.84
Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Int Rev Neurobiol (2004) 0.83
Birth origin differentially affects depressive-like behaviours: are captive-born cynomolgus monkeys more vulnerable to depression than their wild-born counterparts? PLoS One (2013) 0.83
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. J Neurosci (2012) 0.83
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J Neurochem (2003) 0.82
Dopamine-dependent long-term depression at subthalamo-nigral synapses is lost in experimental parkinsonism. J Neurosci (2013) 0.82
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Mov Disord (2014) 0.81
High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism. FASEB J (2004) 0.81
Asymmetrically lesioned mesencephalon in healthy rodents: call for caution. Brain Res (2004) 0.81
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther (2004) 0.81
Genes regulated in MPTP-treated macaques and human Parkinson's disease suggest a common signature in prefrontal cortex. Neurobiol Dis (2010) 0.80
Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neurosci Lett (2007) 0.79
Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clin Neuropharmacol (2004) 0.79
Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiol Dis (2003) 0.79
Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease. Eur J Neurosci (2007) 0.79
Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice. Psychopharmacology (Berl) (2006) 0.78
Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. Sci Rep (2012) 0.78
Experimental reappraisal of continuous dopaminergic stimulation against L-dopa-induced dyskinesia. Mov Disord (2012) 0.78
Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia. Parkinsonism Relat Disord (2009) 0.78
Migration and differentiation of human mesenchymal stem cells in the normal rat brain. Neurol Res (2010) 0.78
Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. Neurobiol Aging (2012) 0.78
Intra-axonal protein aggregation in the peripheral nervous system. J Peripher Nerv Syst (2014) 0.78
High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster. Neurobiol Dis (2009) 0.78
Subthalamic stimulation increases striatal tyrosine hydroxylase phosphorylation. Neuroreport (2008) 0.77
Preclinical development of gene therapy for Parkinson's disease. Exp Neurol (2007) 0.77
The deafferented nonhuman primate is not a reliable model of intractable pain. Neurol Res (2003) 0.77
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord (2003) 0.77
What should be said to the lay public regarding ADHD etiology. Am J Med Genet B Neuropsychiatr Genet (2011) 0.77
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron (2016) 0.76
High frequency stimulation of the entopeduncular nucleus has no effect on striatal dopaminergic transmission. Neurochem Int (2004) 0.76
Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortex. Neurochem Int (2004) 0.76
Toward an animal model of restless legs syndrome? Mov Disord (2012) 0.76